SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma

被引：1

作者：

Chan, S. L. ^{[1
]}

Sangro, B. ^{[2
,3
]}

Kudo, M. ^{[4
]}

Dane, A. ^{[5
]}

Emery, C. ^{[6
]}

Paskow, M. ^{[7
]}

Makowsky, M. ^{[8
]}

Nguyen, B. ^{[9
]}

Rimassa, L. ^{[10
]}

机构：

[1] Chinese Univ Hong Kong, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[2] Clin Univ Navarra, Liver Unit & HPB Oncol Area, Pamplona, Spain

[3] CIBEREHD, Pamplona, Spain

[4] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[5] Danestat Consulting Ltd, Stat, Macclesfield, Cheshire, England

[6] AstraZeneca, Stat, Cambridge, England

[7] AstraZeneca, Global Med Affairs, Gaithersburg, MD USA

[8] AstraZeneca, Oncol R&D, Late Stage Development, Gaithersburg, MD USA

[9] AstraZeneca, Oncol Business Unit Med, Gaithersburg, MD USA

[10] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele & Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Milan, Italy

来源：

关键词：

D O I：

10.1016/j.annonc.2023.10.785

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

206TiP

引用

页码：S1554 / S1554

页数：1